Would A Mortality Endpoint Be The Death Knell For Antibiotics Development?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee meets Dec. 9 to discuss trial designs for community-acquired pneumonia, but a leading expert sees that as a step backward.
You may also be interested in...
Advisory Committee Splits The Difference On CABP Trials
A fierce dispute between researchers and clinicians who think community-acquired bacterial pneumonia drugs should be evaluated by their effect on mortality, and those who favor symptom-based evaluation, is unlikely to be quelled by actions taken at the Dec. 9 meeting of FDA's Anti-Infective Drugs Advisory Committee, which gave each side some of what it wanted
Advisory Committee Splits The Difference On CABP Trials
A fierce dispute between researchers and clinicians who think community-acquired bacterial pneumonia drugs should be evaluated by their effect on mortality, and those who favor symptom-based evaluation, is unlikely to be quelled by actions taken at the Dec. 9 meeting of FDA's Anti-Infective Drugs Advisory Committee, which gave each side some of what it wanted
Former FDA Director: Pneumonia Standards May Be Tough To Follow In Real World R&D
Agency's former microbials head Mark Goldberger highlights guidance flaws at ICAAC.